Ac Immune Sa Stock News

Brokerages expect AC Immune SA (NASDAQ:ACIU) to announce earnings per share (EPS) of $0.11 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for AC Immunes earnings. The lowest EPS estimate is ($0.33) and the highest is $0.90. AC Immune posted earnings per share of ($0.30) in the same []

Wall Street analysts expect AC Immune SA (NASDAQ:ACIU) to post $46.37 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for AC Immunes earnings. The highest sales estimate is $89.65 million and the lowest is $3.08 million. AC Immune reported sales of $1.05 million during the same quarter last []

Walleye Trading LLC purchased a new position in shares of AC Immune SA (NASDAQ:ACIU) during the 2nd quarter, Holdings Channel.com reports. The institutional investor purchased 19,444 shares of the companys stock, valued at approximately $154,000. Several other large investors have also recently made changes to their positions in the company. Balyasny Asset Management LLC boosted []

AC Immune (ACIU) delivered earnings and revenue surprises of 17.24% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

The stock price of AC Immune SA (NASDAQ: ACIU) increased over 9% pre-market today. This is why it happened.

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LAUSANNE, Switzerland, Oct. 25, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today ann

The ardor for shares of AC Immune SA ( ACIU , Financial) has cooled considerably since the company's Aug. 31 announcement of somewhat promising study results for its Alzheimer's drug. The Swiss biotec

LAUSANNE, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseas

LAUSANNE, Switzerland, Sept. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today an

AC Immune's (ACIU) candidate for mild-to-moderate AD meets one of the two co-primary endpoints. Resultantly, the stock price rises 16%

Earlier today, AC Immune SA (NASDAQ:ACIU) announced semorinemab met one of its co-primary endpoints in a mid-stage Alzheimer's disease trial. SVB Leerink notes that semorinemab data is "good news.

AC Immune (ACIU) stock is rising higher on Tuesday after revealing positive results from a recent Alzheimer's disease study. The post ACIU Stock: The Big Alzheimer's News That Has AC Immune Skyrocketi

MIxed results for the company's Alzheimer's disease candidate are good enough for the market today.

The shares of Switzerland-based biopharmaceutical company AC Immune SA (NASDAQ:ACIU) are soaring this morning, up 72.4% to trade at $12.04 at last check.